Figure 1.

In vitro infectability of PBMCs from individuals infected with HIV-2 or controls by different strains of HIV-1. (A) PBMCs from individuals infected with HIV-2 (n = 28) or controls (n = 19) were challenged with 600 TCID₅₀ of HIV-1JR-CSF or HIV-1IIIB and monitored for p24 production over a period of 18 days. Values presented correspond to p24 levels at day 10. HIV-1JR-CSF infection levels in HIV-2-infected PBMCs were significantly lower than those with HIV-1IIIB (Wilcoxon rank-sum test, P = 0.0001). (B) Replication kinetics of HIV-1JR-CSF (filled squares) and HIV-1IIIB (open circles) in PBMCs from individuals infected with HIV-2 that were found to be resistant to HIV-1JR-CSF (Left; n = 14) or susceptible (Center; n = 14) and from negative controls (Right; n = 19). The median values and the first and third quartiles are plotted.